BeOne Medicines (ONC) Interest Expenses (2015 - 2026)

BeOne Medicines (ONC) has reported Interest Expenses for 12 consecutive years, with $32.9 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Interest Expenses rose 153.74% year-over-year to $32.9 million; the TTM figure through Mar 2026 stood at $78.2 million (up 38.18% YoY), while the FY2025 annual figure was $3.6 billion, up 7.18% from the prior year.
• Interest Expenses grew to $32.9 million in Q1 2026 per ONC's latest filing, from $20.6 million in the prior quarter.
• Across five years, Interest Expenses topped out at $32.9 million in Q1 2026 and bottomed at $4.9 million in Q2 2023.
• Historically, Interest Expenses has averaged $11.9 million across 5 years, with a median of $12.1 million in 2023.
• Annual changes were most pronounced in 2022 — Interest Expenses declined 28.46% — and 2024, when it soared 170.56%.
• BeOne Medicines' Interest Expenses stood at $8.2 million in 2022, then jumped by 47.48% to $12.1 million in 2023, then jumped by 32.78% to $16.1 million in 2024, then grew by 28.15% to $20.6 million in 2025, then surged by 59.84% to $32.9 million in 2026.
• Business Quant data shows ONC's Interest Expenses at $32.9 million in Q1 2026, $20.6 million in Q4 2025, and $12.6 million in Q3 2025.